ENVB Enveric Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 890821 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.4%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-204.8%
ROA-175.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.35M | $1.36M | $345,969 | $372,178 | $402,417 | $1.26M | $746,371 | $1.10M |
| SG&A expense | $1.17M | $1.64M | $1.25M | $1.78M | $1.43M | $1.22M | $1.36M | $1.99M |
| Operating income | -$2.56M | -$3.03M | -$1.63M | -$2.19M | -$1.87M | -$2.52M | -$2.19M | -$3.17M |
| Pretax income | -$2.55M | -$3.03M | -$1.63M | -$2.19M | -$1.87M | -$2.52M | -$2.18M | -$3.15M |
| Income tax | — | — | — | — | — | — | — | $7,199 |
| Net income | -$2.55M | -$3.03M | -$1.63M | -$2.19M | -$1.87M | -$2.52M | -$2.18M | -$3.15M |
| EBITDA | -$2.53M | -$2.99M | -$1.60M | -$2.15M | -$1.83M | -$2.48M | -$2.11M | -$3.09M |
| EPS (basic) | -0.57 | -0.76 | -1.08 | — | -10.81 | -11.65 | -14.58 | — |
| EPS (diluted) | -0.57 | -0.76 | -1.08 | — | -10.81 | -11.65 | -14.58 | — |
| Weighted avg. shares (diluted) | 4.48M | 3.99M | 1.51M | — | 313,242 | 216,311 | 149,815 | — |
| Banking | ||||||||
| Net interest income | -$266 | -$292 | -$303 | -$250 | $274 | -$132 | $2 | -$225 |
| Balance sheet | ||||||||
| Cash & equivalents | $5.61M | $8.30M | $4.91M | $4.68M | $3.76M | $2.85M | $4.29M | $2.24M |
| Current assets | $6.25M | $8.79M | $5.38M | $4.94M | $4.17M | $3.31M | $4.83M | $2.73M |
| PP&E, net | $47,622 | $81,929 | $119,927 | $159,234 | $196,521 | $241,082 | $267,279 | $305,777 |
| Intangibles | — | — | — | — | — | — | — | $42,182 |
| Total assets | $6.37M | $8.94M | $5.52M | $5.10M | $4.36M | $3.55M | $5.10M | $3.08M |
| Current liabilities | $644,202 | $861,475 | $460,676 | $918,400 | $905,885 | $1.36M | $1.18M | $1.49M |
| Total liabilities | $644,202 | $861,475 | $460,676 | $918,400 | $905,885 | $1.36M | $1.18M | $1.49M |
| Shareholders' equity | $5.73M | $8.08M | $5.06M | $4.18M | $3.46M | $2.18M | $3.92M | $1.59M |
| Shares outstanding | 4.48M | 3.94M | 1.89M | 1.06M | 518,296 | 3.03M | 2.47M | 56,501 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.65M | -$2.44M | -$2.26M | -$1.78M | -$2.07M | -$1.89M | -$2.39M | -$1.31M |
| Financing cash flow | -$29,055 | $5.84M | $2.50M | $2.69M | $2.99M | $449,096 | $4.45M | $463,448 |
| Depreciation & amortization | $34,919 | $36,826 | $37,240 | $39,485 | $40,369 | $39,980 | $81,024 | $82,487 |
| Stock-based compensation | $198,546 | $125,114 | $88,673 | $240,234 | $186,567 | $205,846 | $193,848 | $471,676 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.